Skip to main content

Table 3 The relationship between the preoperative risk grade and the clinicopathological characteristics

From: Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis

Variables Preoperative risk grade p
0
n = 84
1
n = 196
2
n = 188
Age 58 (50–65) 59 (52–64) 58 (50–66) 0.623
Gender (male) 50 (59.5%) 112 (57.1%) 120 (63.8%) 0.404
Smoking (yes v no) 32 (38.1%) 54 (27.6%) 46 (24.5) 0.067
Drinking (yes) 16 (19.0%) 30 (15.3%) 20 (10.6) 0.150
HBsAg (positive) 46 (54.8%) 92 (46.9%) 64 (34.0%) 0.002
ALT (U/L) 21 (15–37) 29 (16–65) 36 (17–88) < 0.001
ALB (g/L) 38.5 (35.6.2–41.3) 34.1 (33.2–38.2) 30.7 (29.20–34.6) < 0.001
TBIL (μmol/L) 11.6 (8.7–15.4) 13.9 (9.1–22.5) 13.4 (8.9–82.5) < 0.001
Child–Pugh grade (B) 4 (4.8%) 52 (26.5%) 70 (37.2%) < 0.001
Cirrhosis (yes) 42 (50.0%) 82 (41.8%) 98 (52.1%) 0.114
LMR 4.4 (3.1–5.4) 3.4 (1.8–4.4) 2.6 (1.3–3.5) < 0.001
NLR 1.97 (1.38–2.51) 2.3 (1.6–3.3) 3.1 (2.2–5.2) < 0.001
PLR 87.4 (75.7–115.8) 127.7 (94.0–197.8) 234.7 (185.2–274.5) < 0.001
Log10 AFP 0.66 (0.44–1.84) 0.51 (0.32–0.72) 0.51 (0.35–1.09) 0.020
Log10 CEA 0.29 (0.10–0.45) 0.49 (0.25–0.61) 0.49 (0.33–0.70) < 0.001
Log10 CA19-9 1.56 (1.05–2.33) 1.91 (1.34–2.77) 2.21 (1.45–2.97) < 0.001
Tumor number (multiple) 20 (23.8%) 42 (21.4%) 45 (23.9%) 0.821
Tumor diameter (> 5 cm) 50 (59.5%) 90 (45.9%) 68 (36.2%) 0.001
VI (yes) 6 (7.1%) 40 (20.4%) 54 (28.7%) < 0.001
Lymph node metastasis (yes) 16 (19.0%) 54 (27.6%) 88 (46.8%) < 0.001
Tumor differentiation     0.989
 Well 6 (7.1%) 16 (8.2%) 14 (7.4%)  
 Moderate 62 (73.8%) 146 (74.5%) 138 (73.4%)  
 Poor 16 (19.0%) 34 (17.3%) 36 (19.1%)  
Adjuvant chemotherapy (yes) 22 (26.2%) 38 (19.4%) 30 (16.0%) 0.141
Type of hepatectomy (major) 48 (57.1%) 106 (54.1%) 102 (54.3%) 0.884
Blood transfusion (yes) 16 (19.0%) 58 (29.6%) 60 (31.9%) 0.088
  1. HBsAg hepatitis B surface antigen, ALT alanine aminotransferase, ALB albumin, TBIL total bilirubin, LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, AFP α-fetoprotein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, VI vascular invasion